The FDA has awarded a contract to the Kidney Health Initiative for a 3-year project that aims to measure patient preferences and risk tolerance for the creation of novel, renal replacement therapy devices. According to a press release, the project responds to Advancing American Kidney Health, which calls for surveys gauging patient preferences for kidney failure treatments.
“Patient preference information can drive innovation by underscoring the priorities of patients who rely on lifesaving medical devices and interventions,” Anindita Saha, director of Partnerships to Advance Innovation and Regulatory Science in the FDA’s Center for Devices and Radiological Health, said in the release. “As part of our ongoing efforts to advance the goals of the administration’s kidney health initiative, tools like this survey can help the kidney community expedite and design innovative solutions that take into account preferences that matter most to patients when it comes to kidney care and treatment.”
Entitled “Building Capacity to Incorporate Patient Preferences into the Development of Innovative Alternatives to Renal Replacement Therapy,” the project expands on prior work done by the Kidney Health Initiative (KHI). This prior work includes its “Technology Roadmap for Innovative Approaches to Renal Replacement Therapy,” which helped form the Redesign Dialysis prize competition by KidneyX.
Raymond C. Harris
“As the largest public-private partnership in the kidney community, KHI has a unique strength as a convener,” Raymond C. Harris, MD, FASN, co-chair of KHI, said. “We are excited for another opportunity to work closely with the FDA, provide the community new tools, and support the goals of the Advancing American Kidney Health initiative.”